NodThera
PrivateLast Round
IPO
Mar 27, 2026
Total Funding Raised
$145M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
NodThera is a biotechnology company that develops small molecule NLRP3 inflammasome inhibitors for the treatment of chronic inflammatory, cardiometabolic, and neuroinflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NodThera Comparables
Compare NodThera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Halia Therapeutics | 91% | |
| Ventus Therapeutics | 88% | |
| Eli Lilly and Company | 86% |
NodThera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Mar 27, 2026 | ||||
| Series D | Apr 1, 2025 | ||||
| Series B | Jun 3, 2020 | ||||
| Series A | Jun 25, 2018 | ||||
| Seed | Jul 28, 2016 |
Key People
Founding team and executive leadership
NodThera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Epidarex Capital | Series D, Series A, Series B, Seed |
| F-Prime Capital | Series D, Series A, Series B |
| TD Securities | Series B |
| Blue Owl Capital | Series D, Series B |
| 5AM Ventures | Series D, Series B, Series A |
| Novo Holdings | Series D, Series B |
| Sanofi Ventures | Series D, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 113% MoM, from 1.7K to 3.7K.
- Apr 21, 2026
Clinical and commercial plan for ruvonoflast includes Phase 2 data in July 2026 and launch in early 2029.
NodThera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about NodThera's valuation, stock price, and market status.
Is NodThera a public or private company?
NodThera is a private company.
What is the current stock price of NodThera?
NodThera is a private company with no public stock price. No recent secondary market data is available.
How much is NodThera worth (valuation)?
Valuation information for NodThera is not publicly available.
Can I buy NodThera stock?
NodThera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was NodThera's last funding round?
NodThera's most recent funding round was ipo on March 27, 2026.
Who are the main investors in NodThera?
Key investors in NodThera include Epidarex Capital, 5AM Ventures, Novo Holdings, Sofinnova Partners.
Will NodThera IPO soon?
No public IPO plans have been announced for NodThera.
How can I track NodThera secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NodThera's secondary market activity and sign up for updates.